Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483652 · ClinicalTrials.gov registry record · Phase 3
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
A Phase 3 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00483652 is a Phase 3 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 240 participants.
The verdict
NCT00483652, a Phase 3 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
Interventions
- DRUG Placebo
- DRUG Fampridine-SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483652
The ClinicalTrials.gov registry entry for NCT00483652 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00483652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483652 about?
NCT00483652 is a clinical study titled "Study of Fampridine-SR Tablets in Multiple Sclerosis Patients". The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
What is the current status of trial NCT00483652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2007-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00483652?
The interventions under investigation include: Placebo (DRUG), Fampridine-SR (DRUG).
Who is sponsoring clinical trial NCT00483652?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.